메뉴 건너뛰기




Volumn 33, Issue 8, 2015, Pages 916-922

Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and Arimidex, Tamoxifen Alone or in combination randomized trials using the PAM50 risk of recurrence score

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HORMONE; NITRILE; TRIAZOLE DERIVATIVE;

EID: 84924954946     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.6894     Document Type: Article
Times cited : (189)

References (26)
  • 1
    • 0029759541 scopus 로고    scopus 로고
    • Annual hazard rates of recurrence for breast cancer after primary therapy
    • Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 2738-2746
    • Saphner, T.1    Tormey, D.C.2    Gray, R.3
  • 2
    • 0032537396 scopus 로고    scopus 로고
    • Tamoxifen for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group
    • [No authors listed]: Tamoxifen for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
    • (1998) Lancet , vol.351 , pp. 1451-1467
  • 3
    • 34548144485 scopus 로고    scopus 로고
    • Tamoxifen for early breast cancer
    • Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer. Cochrane Database Syst Rev 1:CD000486, 2001
    • (2001) Cochrane Database Syst Rev , vol.1
  • 4
    • 33646789495 scopus 로고    scopus 로고
    • Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial
    • Goss PE: Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial. Semin Oncol 33:S8-S12, 2006
    • (2006) Semin Oncol , vol.33 , pp. S8-S12
    • Goss, P.E.1
  • 5
    • 51049084866 scopus 로고    scopus 로고
    • Residual risk of breast cancer recurrence 5 years after adjuvant therapy
    • Brewster AM, Hortobagyi GN, Broglio KR, et al: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100:1179-1183, 2008
    • (2008) J Natl Cancer Inst , vol.100 , pp. 1179-1183
    • Brewster, A.M.1    Hortobagyi, G.N.2    Broglio, K.R.3
  • 6
    • 84866544308 scopus 로고    scopus 로고
    • Molecular tumor characteristics influence adjuvant endocrine treatment outcome
    • Bianchini G, Pusztai L, Iwamoto T, et al: Molecular tumor characteristics influence adjuvant endocrine treatment outcome. Cancer Res 71:S1-S7, 2011
    • (2011) Cancer Res , vol.71 , pp. S1-S7
    • Bianchini, G.1    Pusztai, L.2    Iwamoto, T.3
  • 7
    • 84881257906 scopus 로고    scopus 로고
    • Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence
    • Zhang Y, Schnabel CA, Schroeder BE, et al: Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 19:4196-4205, 2013
    • (2013) Clin Cancer Res , vol.19 , pp. 4196-4205
    • Zhang, Y.1    Schnabel, C.A.2    Schroeder, B.E.3
  • 8
    • 84883456580 scopus 로고    scopus 로고
    • Comparative performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: A TransATAC Study
    • Sgroi DC, Sestak I, Cuzick J, et al: Comparative performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: A TransATAC Study. Cancer Res 72:S1-S9, 2012
    • (2012) Cancer Res , vol.72 , pp. S1-S9
    • Sgroi, D.C.1    Sestak, I.2    Cuzick, J.3
  • 9
    • 84890426904 scopus 로고    scopus 로고
    • The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients
    • Dubsky P, Brase JC, Jakesz R, et al: The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 109:2959-2964, 2013
    • (2013) Br J Cancer , vol.109 , pp. 2959-2964
    • Dubsky, P.1    Brase, J.C.2    Jakesz, R.3
  • 10
    • 62449131093 scopus 로고    scopus 로고
    • Supervised risk predictor of breast cancer based on intrinsic subtypes
    • Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 1160-1167
    • Parker, J.S.1    Mullins, M.2    Cheang, M.C.3
  • 11
    • 78049453780 scopus 로고    scopus 로고
    • A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer
    • Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232, 2010
    • (2010) Clin Cancer Res , vol.16 , pp. 5222-5232
    • Nielsen, T.O.1    Parker, J.S.2    Leung, S.3
  • 12
    • 84884762173 scopus 로고    scopus 로고
    • Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
    • Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783-2790, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 2783-2790
    • Dowsett, M.1    Sestak, I.2    Lopez-Knowles, E.3
  • 13
    • 84893424611 scopus 로고    scopus 로고
    • Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
    • Gnant M, Filipits M, Greil R, et al: Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25:339-345, 2014
    • (2014) Ann Oncol , vol.25 , pp. 339-345
    • Gnant, M.1    Filipits, M.2    Greil, R.3
  • 14
    • 37449028688 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
    • Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
    • (2008) Lancet Oncol , vol.9 , pp. 45-53
    • Forbes, J.F.1    Cuzick, J.2
  • 15
    • 41949104971 scopus 로고    scopus 로고
    • Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial
    • Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 1059-1065
    • Dowsett, M.1    Allred, C.2    Knox, J.3
  • 16
    • 84857508799 scopus 로고    scopus 로고
    • Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group
    • Dubsky PC, Jakesz R, Mlineritsch B, et al: Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 30:722-728, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 722-728
    • Dubsky, P.C.1    Jakesz, R.2    Mlineritsch, B.3
  • 17
    • 81155133281 scopus 로고    scopus 로고
    • Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer
    • Cuzick J, Dowsett M, Pineda S, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29:4273-4278, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 4273-4278
    • Cuzick, J.1    Dowsett, M.2    Pineda, S.3
  • 19
    • 38849091997 scopus 로고    scopus 로고
    • Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
    • Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27:157-172, 2008
    • (2008) Stat Med , vol.27 , pp. 157-172
    • Pencina, M.J.1    D'Agostino, R.B.2    D'Agostino, R.B.3
  • 20
    • 78649477601 scopus 로고    scopus 로고
    • Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
    • Pencina MJ, D'Agostino RB Sr, Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11-21, 2011
    • (2011) Stat Med , vol.30 , pp. 11-21
    • Pencina, M.J.1    D'Agostino, R.B.2    Steyerberg, E.W.3
  • 21
    • 78649603622 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
    • Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
    • (2010) Lancet Oncol , vol.11 , pp. 1135-1141
    • Cuzick, J.1    Sestak, I.2    Baum, M.3
  • 22
    • 84883449158 scopus 로고    scopus 로고
    • Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study
    • abstr P2-10-02
    • Gnant M, Filipits M, Mlineritsch B, et al: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study. Cancer Res 72, 2012 (suppl 3: abstr P2-10-02)
    • (2012) Cancer Res , vol.72
    • Gnant, M.1    Filipits, M.2    Mlineritsch, B.3
  • 23
    • 80052641331 scopus 로고    scopus 로고
    • Biologic markers determine both the risk and the timing of recurrence in breast cancer
    • Esserman LJ, Moore DH, Tsing PJ, et al: Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 129:607-616, 2011
    • (2011) Breast Cancer Res Treat , vol.129 , pp. 607-616
    • Esserman, L.J.1    Moore, D.H.2    Tsing, P.J.3
  • 24
    • 24744450378 scopus 로고    scopus 로고
    • Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17
    • Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1262-1271
    • Goss, P.E.1    Ingle, J.N.2    Martino, S.3
  • 25
    • 84873868973 scopus 로고    scopus 로고
    • Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole
    • Goss PE, Ingle JN, Martino S, et al: Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 24:355-361, 2013
    • (2013) Ann Oncol , vol.24 , pp. 355-361
    • Goss, P.E.1    Ingle, J.N.2    Martino, S.3
  • 26
    • 42949104549 scopus 로고    scopus 로고
    • Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial
    • Mamounas EP, Jeong JH, Wickerham DL, et al: Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26:1965-1971, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 1965-1971
    • Mamounas, E.P.1    Jeong, J.H.2    Wickerham, D.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.